175417-85-3 Usage
Uses
Used in Pharmaceutical Industry:
2-Pyrrolidinemethanamine, N,1-dimethyl-,(S)-(9CI) is used as a building block for the synthesis of various pharmaceutical molecules. Its chiral nature and unique structure make it a valuable component in the development of new drugs with improved efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical industry, 2-Pyrrolidinemethanamine, N,1-dimethyl-,(S)-(9CI) is used as a precursor for the synthesis of various agrochemicals, such as pesticides and herbicides. Its unique properties and stereochemistry contribute to the development of more effective and targeted agrochemicals.
Used as a Chiral Catalyst:
Due to its chiral nature, 2-Pyrrolidinemethanamine, N,1-dimethyl-,(S)-(9CI) can be used as a chiral catalyst in various chemical reactions. Its ability to selectively promote certain reactions can lead to the production of enantiomerically pure compounds, which are important in various applications, including pharmaceuticals and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 175417-85-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,5,4,1 and 7 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 175417-85:
(8*1)+(7*7)+(6*5)+(5*4)+(4*1)+(3*7)+(2*8)+(1*5)=153
153 % 10 = 3
So 175417-85-3 is a valid CAS Registry Number.
175417-85-3Relevant academic research and scientific papers
Tetrahydropyridopyrimidine compound with anti-tumor activity
-
Paragraph 0184-0189; 0192-0193, (2020/12/30)
The invention provides a tetrahydropyridopyrimidine compound shown as a formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the tetrahydropyridopyrimidine compound and the pharmaceutically acceptable salt thereof, and application of the tetrahydropyridopyrimidine compound or the pharmaceutically acceptable salt thereof in the preparation of a drug forpreventing and/or treating KRAS G12C mutant tumors.
